Combination Therapy Shows Potential in Psoriasis, Obesity

• by Kathryn Wighton

• May 20, 2026

FDA Expands Guselkumab Label in PsA

Phase 3b APEX findings support the addition of structural joint damage inhibition data to the prescribing information.

• by Kathryn Wighton

• May 29, 2026

• 2 min

Skin barrier dysfunction and correlation with the onset and progression of psoriasis

• by Ying Wang, Yanyang Liang, Jianxiao Xing, Junqin Li, Kaiming Zhang

• June 30, 2026

Understanding Social Drivers of Health Among US Adults with Psoriasis from Different Races and Ethnicities

• by Victoria Barbosa, Tina Bhutani-Jacques, Valerie D. Callender, Elizabeth D. Bacci, Evangeline Pierce, Beth Mitchell, Julia R. Correll, Nicole Huang

• July 15, 2026